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Abstract 
In a Guidance document, the American FDA recommends the use of a Minolta chromameter 
rather than the human eye for the quantitative assessment of the pharmacodynamic blanching 
response produced by topical application of corticosteroids. The purpose of this study was to 
compare the appropriateness of the human eye and two models of chromameter for the 
estimation of skin blanching, in terms of the quality of the data generated by each method. 
The corticosteroid-induced skin blanching from four different betamethasone 17-valerate 
cream formulations was compared in a typical human skin blanching trial. The optimized 
assay methodology routinely practised in our laboratories was utilized. The blanching 
responses were assessed visually by three trained, independent observers and recorded by 
two chromameters (Minolta model CR-200 and model CR-300). The topical availability of 
the four creams was determined using visual scoring and chromameter measurements. All 
data were manipulated in such a manner as to produce a blanching response versus time 
profile from which AUBC analysis could be performed. Good correlation was observed 
between the visual assessments made by three independent observers. In contrast, moderate 
correlation was determined between visual, CR-200 and CR-300 measurements. 
Surprisingly, no direct linear relationship between the AUBCs produced by the two 
chromameters was observed indicating that the quality of the data obtained from the two 
instruments may not be equal. This investigation also indicated that the use of the 
chromameter is not completely objective. Visual scoring and chromameter measurement 
produce data sets that differ in quality. Each procedure needs to be validated and 
investigators have to be trained for both visual assessment and the operation of the 
chromameter, particularly with regard to the manipulation of the measuring head of the 
instrument.  
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1. Introduction 
The human skin blanching assay has been shown to be a useful tool for the comparison of the 
potency of different topical corticosteroid formulations, since a direct correlation has been 
demonstrated between the intensity of corticosteroid-induced skin blanching and clinical 
efficacy [1, 2, 3]. The assay is also useful for the comparison of the topical availability of 
corticosteroid formulations containing the same concentration of the same corticosteroid [4, 
5] and has, thus, been used extensively in topical corticosteroid bioequivalence testing for 
regulatory purposes.  
Until recently, the assessment of the intensity of corticosteroid-induced skin blanching has 
been performed visually by one or more trained investigators, using an ordinal data scale. 
This method has been criticized as the visual scoring results were reported to lack 
reproducibility, due to the inherent subjectivity of the observers [6]. Recently, it has been 
shown by Haigh et al. [7, 8] that it is possible to perform the visually assessed skin blanching 
assay, in such a way that reproducible and consistent results are obtained.  
In 1995, the American Food and Drug Administration (FDA) released a Guidance document 
[6], which attempted to standardize the technique of in vivo topical corticosteroid 
formulation bioequivalence testing. In this directive it is suggested that, with the availability 
of increasingly sophisticated and precise analytical methods for the detection of 
pharmacodynamic responses, the subjective visual assessment of corticosteroid-induced skin 
blanching is no longer appropriate. As an alternative, the Guidance suggests the use of the 
Minolta chromameter for the quantification of the intensity of induced vasoconstriction.  
Chromameters are compact portable instruments used for the assessment of surface colour 
based on the tristimulus analysis of a reflected xenon light pulse. In this investigation skin 
colours were measured using the CIE 1976 (L*a*b) system [9], which simulates the 
sensitivity of the human eye. The L-value is the lightness variable and the a- and b-values are 
the chromaticity co-ordinates (red-green and blue-yellow, respectively). These three values 
can be used to define a point in three-dimensional space that characterizes a colour in 
absolute terms. The magnitude of the difference between two colours, as perceived by the 
human eye, is proportional to the distance between two points defining those colours in the 
three-dimensional space. The difference between the two colours, the Euclidean distance 
(∆E), is defined by Eq. 1 [9]: 
                      (1) 
 
The aim of the present study was to compare the visual results obtained by three independent 
observers, with the skin colour measurements performed with two chromameters. Four 
corticosteroid cream formulations with very similar blanching profiles were chosen in order 
to investigate the sensitivity of the different assessment methods. According to a previous 
interlaboratory comparison of the Minolta CR-200 and CR-300 chromameters performed by 
Fullerton et al. [10], both chromameters showed very good reproducibility, with low 
coefficients of variation determined on standard colour plates, but precision on human 
forearm was significantly lower.  
 
2. Materials and methods 
Four cream formulations, each containing 0.12% betamethasone 17-valerate were chosen for 
this investigation: Adco-Betamethasone (Adcock Ingram, South Africa), Betnovate (Glaxo-
Wellcome, South Africa), Celestoderm-V (Schering-Plough, South Africa) and Lenovate 
(Pharmacare-Lennon, South Africa). Two models of Minolta chromameter were used: the 
CR-200 (Minolta, USA), and the CR-300 which underwent a standard inspection procedure 
(Minolta, Switzerland) prior to this investigation.  
The methodology of the human skin blanching assay routinely practised in our laboratories 
[7] was modified to comply with the aims of this study. Twelve healthy male and female, 
light-skinned volunteers (aged from 18–25 years) who had been pre-screened for positive 
blanching response were selected. Ethical approval was obtained from the Rhodes University 
Ethical Standards Committee in compliance with the 1964 Declaration of Helsinki and its 
subsequent amendments. Written informed consent was obtained from each subject.  
2.1. Application of formulation 
All volunteers were processed sequentially at 5-min intervals in order to minimize any 
possible effects of environmental variables, such as temperature and humidity. Six adhesive 
labels, from which two 7×7 mm squares had been punched, were applied to the flexor aspect 
of both forearms to demarcate a total of 12 application sites per arm of each volunteer. Each 
formulation was applied to three of the twelve demarcated sites in a random manner [5] and 
four adjacent sites were utilized for the unmedicated control. Four different, random 
application patterns were used such that, in total, each formulation was represented at all sites 
along the entire length of the forearm; this being essential because of the forearm gradient in 
the pharmacodynamic response [11]. The formulations were applied by extrusion of four 
stripes (equivalent to approximately 3.2 mg) from a 1-ml syringe to each designated site in a 
double blind, randomized manner. The extruded formulations were spread evenly over the 
application sites using a glass rod, and were covered with a porous Perspex frame to prevent 
accidental removal of the applied formulations. After a contact time of six h, the protective 
covers and adhesive labels were removed and each application site was separately washed 
using cotton-tipped buds and distilled water, and patted dry.  
2.2. Visual assessment of blanching response 
Visual response assessments were made independently by three experienced observers [5] at 
7, 8, 9, 10, 12, 13, 14, 15, 16, 18, 26, 28 and 32 h after product application. Standard 
overhead fluorescent lighting was used to illuminate the horizontally-placed arms of the 
volunteers. Responses were graded subjectively by each observer using an ordinal scale 
where 0= no blanching, 1= slight blanching, 2= more intense blanching, 3= general, even and 
distinct blanching and 4= marked and very intense blanching with distinct margins on all 
sides. The percentage of the total possible score (%TPS) was calculated [12] for each 
formulation and plotted against time in hours after product application, to produce blanching 
profiles for each individual observer and averaged for the whole data set. The trapezoidal 
rule was used to calculate the 0–32 h area under the pooled observer blanching curve 
(AUBC) for each formulation and arm.  
2.3. Chromameter assessment of blanching response 
The instruments were calibrated using the white calibration plate (CR-A43) immediately 
before the study. Baseline readings (zero time) were taken at all sites (including the untreated 
control sites) prior to the application of the formulations. Thereafter, blanching responses at 
all application sites and at four untreated control sites were assessed at the same times as the 
visual assessments. Simultaneous readings were taken with both the CR-200 and the CR-300 
chromameters (L-, a-, and b-scale parameters) in the same laboratory by two different 
investigators. The arms of the volunteers were placed horizontally for these measurements, 
and special care was taken with the perpendicular placement of the chromameter probe on 
the forearm. The manipulation of the probe required special attention so as to prevent 
changes in skin colour due to pressure of the head on the skin [10, 13], and inaccurate 
alignment of the centre of the reading head over the formulation application site.  
At each observation time, the recorded L-, a- and b-values for each medicated and 
unmedicated site were corrected, by subtracting the baseline (time zero) values to yield 
baseline-corrected values. In addition, the means of the four (baseline-corrected), 
unmedicated control site values for each arm at each reading time were further subtracted 
from the baseline-corrected values for the medicated sites at each observation time, to yield 
the ∆L, ∆a and ∆b values (Eq. 2) [6]: 
Delta values=(Mt=x−Mt=0)−(Ut=x−Ut=0)                 (2) 
 
where M is the L-, a-, or b-value at a medicated site, U is the corresponding average value of 
four unmedicated sites for that arm and t is the observation time (0= premedication, x = 
reading time). This double-correction procedure is only suggested for the a-scale data in the 
FDA Guidance as the L- and b-scale data are not advocated for use in the bioequivalence 
assessment procedure.  
The mean ∆L-, ∆a- and ∆b-values of all formulations were calculated and plotted against 
time. The areas under the ∆L and ∆a curves (AUBC) were calculated for each preparation 
using the trapezoidal rule from 0 to 32 h. The b-scale data are not presented since there is 
negligible change in the b-scale values with increased blanching. From the mean ∆L, ∆a and 
∆b values, the absolute colour differences (∆E) were calculated for each formulation 
according to Eq. 1 and compared with the %TPS values from the visual assessment.  
2.4. Statistical analysis of AUBC data 
The AUBC values obtained from the left and right arms were averaged to obtain one value 
for each of the 12 volunteers. Locke's method was used to calculate confidence intervals 
from visual and chromameter AUBC data according to the directive of the FDA Guidance [6, 
14]. AUBC data sets (n=12) for two formulations (reference (R) and test (T) formulation) 
were compared using Eq. 3 to obtain an exact confidence interval: 
                                   (3) 
 
where t =2.2010 for the 97.5th percentile (95% confidence interval) of the t-distribution for 
11 (n −1) degrees of freedom [15], and G is required to be <1. , are sample means 
and are sample variances of Test and Reference Product, respectively, is the 
sample covariance. 
 
                                                  (3a) 
 
                   (3b) 
 To investigate the relationship between visual and chromameter data, all the 48 AUBC 
values from all the formulations in all volunteers (4 formulations×12 volunteers) obtained by 
one of the assessment methods (visual, CR-200, or CR-300) were related to another AUBC 
value data set obtained by a different assessment method. The correlation coefficients of the 
regression lines were further transformed according to Eq. 4, to obtain normalized data [16]. 
                                       (4) 
 
significant correlation was found and the null hypothesis ρ=0 was rejected when z was 
outside the 95% confidence interval of 0±0.29217 [16]. Theoretically, there should be a 
linear relationship between the results obtained using the two different chromameters, i.e. the 
regression line should have a slope of unity and an intercept at the origin. A regression 
analysis was performed to investigate the linear association of the ∆a-scale AUBCs produced 
from the CR-200 and CR-300 data.  
3. Results and discussion 
Fig. 1 depicts the mean results of the visually-assessed blanching profiles for the three 
observers and four cream formulations. To maintain clarity, only a few representative error 
bars are shown in Fig. 1, Fig. 2 and Fig. 3. Table 1 lists the areas under the visual blanching 
curves scored by the individual observers and the correlations between the results of different 
observers. The same rank order was observed for the results of all observers and the inter-
individual precision of the visual blanching assessments, as determined by the correlation of 
the AUBC values obtained by each individual observer, was excellent.  
 
Fig. 1. Visually assessed blanching profiles of Adco-Betamethasone (circle), Betnovate (square), Celestoderm-
V (rhombus) and Lenovate (triangle), obtained by the pool of three observers. Some representative error bars 
(standard deviation) are given.  
  
 
Fig. 2. Blanching profiles of chromameter results: ∆a-scale values for Adco-Betamethasone (circle), Betnovate 
(square), Celestoderm-V (rhombus) and Lenovate (triangle). Some representative error bars (standard deviation) 
are given.  
 
 
 
 
  
 
 
Fig. 3. Blanching profiles of chromameter results: absolute colour difference ∆E-values for Adco-
Betamethasone (circle), Betnovate (square), Celestoderm-V (rhombus) and Lenovate (triangle).  
 
 
 
 
 
 
 
Table 1. Areas under the visual blanching curves (AUBC) for each observer, and coefficient of AUBC-
correlation between observers 
 
The ∆a-scale values determined using the CR-200 and CR-300 (Fig. 2) were plotted against 
time as recommended by the FDA guidance [6]. The total absolute colour differences 
between application sites at each observation time are depicted in Fig. 3 as Euclidean 
distances versus time. Table 2 lists the mean areas under the visually-assessed blanching 
response curves and under the ∆L, ∆a and ∆E curves.  
 
Table 2. AUBC values from visual assessment (observer-pool) and chromameter CR-200 and CR-300 ∆L, ∆a, 
and ∆E-data  
 
Compared with the visual graph, the curves of the ∆a values obtained with both 
chromameters show similar shapes. In each of these graphs, the plots of Betnovate, 
Celestoderm-V and Adco-Betamethasone are almost identical, whereas the plot of Lenovate 
shows a larger AUBC. The areas under the ∆a curve are comparable for both measuring 
devices, whereas the areas under the ∆L curves (data not shown) obtained by the CR-200 
chromameter were larger by a factor of 1.9 compared with the CR-300, and no significant 
differences between the products were detected. As can be seen from Fig. 3, the graph 
obtained using the CR-300 measurements, which represents the Euclidean distances between 
the baseline-adjusted medicated and baseline-adjusted unmedicated sites, correlated with the 
visual data, and the comparison resulted in a correlation coefficient of 0.714. The divergent 
values of the CR-200 L-scale measurements, therefore, influenced the respective ∆E-curve.  
Reasonable correlation was observed between visual and ∆a AUBC values (r=−0.799 for 
CR-300 and r=−0.716 for CR-200) and visual and ∆L AUBC values (r=0.683 for CR-300 
and r=0.584 for CR-200). Correlation within the same colour coordinate AUBC values 
determined by the two different devices were r=0.579 for ∆a AUBC values and r=0.375 for 
∆L AUBC values. Regression analysis showed that there were no direct linear relations 
between the measurements obtained by utilization of the two different chromameters. For the 
∆a AUBC values, the slope of the regression line was 0.387 (0.225 − 0.549; 95% CI) and the 
intercept was −24.3 (−31.8 − −16.8; 95% CI). In case of ∆L AUBC values a slope of 0.278 
(0.074 − 0.482; 95% CI) and an intercept of 20.6 (4.3 − 36.9; 95% CI) was obtained.  
Table 3 lists the percentage ratios of the pharmacodynamic blanching responses of the 
superior Lenovate cream compared with the three other formulations. The visually-assessed 
AUBC for Lenovate was significantly higher than those of all the other products.  
 
Table 3. Ratio of AUBCs between formulations in percent (and range of 95% CI calculated according to 
Locke's method is given)  
 
The results obtained with the two models of Minolta chromameter demonstrated an 
acceptable similarity. Whereas Lenovate cream showed superiority over Adco-
Betamethasone cream in both chromameter assessments, the superiority over Celestoderm-V 
and Adco-Betamethasone was lesser and close to the borderline of significance in both cases. 
It should be stressed that in the case of the visual assessment, the blanching reaction was 
compared with the skin surrounding the application site, whereas with the chromameter, 
blanching was compared with the skin colour at adjacent unmedicated sites, although one 
would not expect this to make appreciable difference to the results.  
These results further confirm previous observations that the chromameter is better at 
distinguishing between markedly different blanching intensities, and produces superior 
results when the blanching is intense. Discrimination is poorer when products that are only 
marginally different are compared and measurement sensitivity is lower compared with 
visual assessment. This poses a problem for bioequivalence assessments, where formulations 
that produce only subtle differences in skin blanching are compared.  
4. Conclusion 
A high interinstrumental reproducibility between both models of chromameters has been 
reported [10]. However, the reproducibility of readings from in vivo forearm skin was not as 
good as that from a standard colour plate. The lower reproducibility on human skin is 
considered to be evoked by physiological fluctuations of forearm skin colour and investigator 
related factors, such as the perpendicular alignment and the application force of the 
measuring head on the skin sites. The results obtained in this study with the CR-300 
chromameter showed better correlation with the visually-assessed response and are more 
consistent than those obtained with the CR-200. This difference might be explained rather by 
the fact that the chromameters were operated by two individuals, than by difference of the 
two chromameter models. Since the measuring head alignment, contact pressure and 
positioning over the reading site are techniques which are operator dependent; there is 
obviously some subjectivity in the results obtained. This operator dependency can be 
responsible for any interlaboratory variability of chromameter results, which might occur.  
Our results illustrate that, even though the FDA [6] considers the chromameter as an 
‘objective', quantifiable measuring device compared with the ‘subjective' visual scoring, the 
measurements obtained by the chromameter are operator dependent and are, therefore, also 
subjective. The operator requires extensive training and experience before reliable and 
reproducible results can be produced. In addition, personal experience has suggested that 
self-assessment with the chromameter may produce superior results compared with operator-
assessment, since the alignment, positioning and surface pressure can be judged more 
precisely on one's own arm than on the arm of another subject.  
Although no linear relationship was detected between the AUBC values of the CR-200 and 
CR-300 chromameter results, acceptable reproducibility was achieved by the two measuring 
devices. However, care must be taken when the chromameter is used in a human skin 
blanching trial as it has been observed that the results are not completely objective, and the 
overall precision of the instrumental method must be considered when very similar 
formulations are compared. It seems obvious, therefore, that before a chromameter is utilized 
in this way, a validation procedure should be performed to ensure the reliability of results in 
any bioequivalence study.  
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